Dr Bruce Chabner joins Peregrine as clinical advisor
This article was originally published in Scrip
Executive Summary
Peregrine Pharmaceuticals (US) has elected cancer researcher Dr Bruce Chabner as a clinical advisor on the design of clinical trials for its bavituximab cancer programme. Dr Chabner is clinical director of the Massachusetts General Hospital (MGH) Cancer Center, chief of haematology and oncology at MGH and a professor of medicine at Harvard Medical School. Before that, he had a 25-year career at the National Cancer Institute, including serving as scientific director and director of the division of cancer treatment.
You may also be interested in...
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.